Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection

AIDS

Volumn 30, Issue 17, 2016, Pages 2625-2633

  Kelesidis, Theodoros ^a   Jackson, Nicholas ^a   McComsey, Grace A ^b   Wang, Xiaoyan ^a   Elashoff, David ^a   Dube, Michael P ^c   Brown, Todd T ^d   Yang, Otto O ^a   Stein, James H ^e   Currier, Judith S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

HIV; Immune activation; Inflammation; Oxidized lipoproteins

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; C REACTIVE PROTEIN; CD14 ANTIGEN; CD16 ANTIGEN; CD163 ANTIGEN; CD28 ANTIGEN; CD57 ANTIGEN; D DIMER; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE; HIGH DENSITY LIPOPROTEIN; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; OXIDIZED HIGH DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEINASE INHIBITOR; RALTEGRAVIR; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; IL6 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; LIPOPROTEIN;

ANTIRETROVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFLAMMATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MONOCYTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ADULT; BLOOD; CHEMISTRY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; LONGITUDINAL STUDY; MALE; OXIDATION REDUCTION REACTION; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; SUSTAINED VIROLOGIC RESPONSE; T LYMPHOCYTE;

ADULT; ANTI-HIV AGENTS; ANTIGENS, CD; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; C-REACTIVE PROTEIN; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HIV INFECTIONS; HUMANS; INFLAMMATION; INTERLEUKIN-6; LIPOPROTEINS; LONGITUDINAL STUDIES; MALE; MONOCYTES; OXIDATION-REDUCTION; PROSPECTIVE STUDIES; SUSTAINED VIROLOGIC RESPONSE; T-LYMPHOCYTES;

EID: 84986236297     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000001238     Document Type: Article

References (50)

1. Paiardini M, Muller-Trutwin M. HIV-associated chronic immune activation. Immunol Rev 2013; 254: 78-101.
2. Lederman MM, Calabrese L, Funderburg NT, Clagett B, Medvik K, Bonilla H, et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis 2011; 204: 1217-1226.
3. Bhattacharyya A, Chattopadhyay R, Mitra S, Crowe SE. Oxidative stress: An essential factor in the pathogenesis of gastrointestinal mucosal diseases. Physiol Rev 2014; 94: 329-354.
4. Price TO, Ercal N, Nakaoke R, Banks WA. HIV-1 viral proteins gp120 and Tat induce oxidative stress in brain endothelial cells. Brain Res 2005; 1045: 57-63.
5. Schroeder C. Cholesterol-binding viral proteins in virus entry and morphogenesis. Subcell Biochem 2010; 51: 77-108.
6. Freigang S, Kain L, Teyton L. Transport and uptake of immunogenic lipids. Mol Immunol 2013; 55: 179-181.
7. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011; 12: 204-212.
8. Laczik R, Szodoray P, Veres K, Lakos G, Sipka S, Szegedi G, Soltész P. Oxidized LDL induces in vitro lymphocyte activation in antiphospholipid syndrome. Autoimmunity 2010; 43: 334-339.
9. Graham LS, Parhami F, Tintut Y, Kitchen CM, Demer LL, Effros RB. Oxidized lipids enhance RANKL production by T lymphocytes: Implications for lipid-induced bone loss. Clin Immunol 2009; 133: 265-275.
10. Tsimikas S, Miller YI. Oxidative modification of lipoproteins: Mechanisms, role in inflammation and potential clinical applications in cardiovascular disease. Curr Pharm Des 2011; 17: 27-37.
11. Bochkov VN, Oskolkova OV, Birukov KG, Levonen AL, Binder CJ, Stockl J. Generation and biological activities of oxidized phospholipids. Antioxid Redox Signal 2010; 12: 1009-1059.
12. Kaji H. High-density lipoproteins and the immune system. J Lipids 2013; 2013: 684903.
13. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: Atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 2011; 8: 222-232.
14. Kelesidis T, Currier JS, Huynh D, Meriwether D, Charles-Schoeman C, Reddy ST, et al. A biochemical fluorometric method for assessing the oxidative properties of HDL. J Lipid Res 2011; 52: 2341-2351.
15. Kelesidis T, Yang OO, Currier JS, Navab K, Fogelman AM, Navab M. HIV-1 infected patients with suppressed plasma viremia on treatment have pro-inflammatory HDL. Lipids Health Dis 2011; 10: 35.
16. Kelesidis T, Flores M, Tseng CH, Currier JS, Yang OO. HIV-infected adults with suppressed viremia on antiretroviral therapy have dysfunctional HDL that is associated with T cell activation. Abstract 662. ID Week 2012, San Diego, CA 2012.
17. Kelesidis T, Roberts CK, Huynh D, Martínez-Maza O, Currier JS, Reddy ST, Yang OO. A high throughput biochemical fluorometric method for measuring lipid peroxidation in HDL. PLoS One 2014; 9: E111716.
18. Zanni MV, Kelesidis T, Fitzgerald ML, Lo J, Abbara S, Wai B, et al. HDL redox activity is increased in HIV-infected men in association with macrophage activation and noncalcified coronary atherosclerotic plaque. Antivir Ther 2014; 19: 805-811.
19. Park KH, Cho KH. High-density lipoprotein (HDL) from elderly and reconstituted HDL containing glycated apolipoproteins A-I share proatherosclerotic and prosenescent properties with increased cholesterol influx. J Gerontol A: Biol Sci Med Sci 2011; 66: 511-520.
20. Park KH, Shin DG, Cho KH. Dysfunctional lipoproteins from young smokers exacerbate cellular senescence and atherogenesis with smaller particle size and severe oxidation and glycation. Toxicol Sci 2014; 140: 16-25.
21. Chou JP, Effros RB. T cell replicative senescence in human aging. Curr Pharm Des 2013; 19: 1680-1698.
22. Kaplan RC, Sinclair E, Landay AL, Lurain N, Sharrett AR, Gange SJ, et al. T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis 2011; 203: 452-463.
23. Kelesidis T, Currier JS, Huynh D, Park S, Ng HL, Yang OO. Dysfunctional high density lipoprotein directly upregulates T cell activation in HIV-1 infection. [abstract 258]. Conferences on Retroviruses and Opportunistic Infections (CROI 2014) March 3-6, 2014 Boston, Massachusetts.
24. Zidar DA, Juchnowski S, Ferrari B, Clagett B, Pilch-Cooper HA, Rose S, et al. Oxidized LDL levels are increased in HIV infection and may drive monocyte activation. J Acquir Immune Defic Syndr 2015; 69: 154-160.
25. Kelesidis T, Tran TT, Stein JH, Brown TT, Moser C, Ribaudo HJ, et al. Changes in inflammation and immune activation with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy: ACTG 5260s. Clin Infect Dis 2015; 61: 651-660.
26. Brown TT, Chen Y, Currier JS, Ribaudo HJ, Rothenberg J, Dubé MP, et al. Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV- 1-infected individuals. J Acquir Immune Defic Syndr 2013; 63: 323-330.
27. McComsey GA, Moser C, Currier J, Ribaudo HJ, Paczuski P, Dubé MP, et al. Body composition changes after initiation of raltegravir or protease inhibitors: ACTG A5260s. Clin Infect Dis 2016; 62: 853-862.
28. Huang H, Mai W, Liu D, Hao Y, Tao J, Dong Y. The oxidation ratio of LDL: A predictor for coronary artery disease. Dis Markers 2008; 24: 341-349.
29. Kelesidis T, Roberts CK, Huynh D, Martínez-Maza O, Currier JS, Reddy ST, Yang OO. A high throughput biochemical fluorometric method for measuring lipid peroxidation in HDL. PLoS One 2014; 9: E111716.
30. Kelesidis T, Yang OO, Kendall MA, Hodis HN, Currier JS. Dysfunctional HDL and progression of atherosclerosis in HIV-1-infected and -uninfected adults. Lipids Health Dis 2013; 12: 23.
31. Kelesidis T, Reddy ST, Huynh D, Meriwether D, Fogelman AM, Navab M, Yang OO. Effects of lipid-probe interactions in biochemical fluorometric methods that assess HDL redox activity. Lipids Health Dis 2012; 11: 87.
32. Zanni MV, Kelesidis T, Fitzgerald ML, Lo J, Abbara S, Wai B, et al. HDL redox activity is increased in HIV-infected men in association with macrophage activation and noncalcified coronary atherosclerotic plaque. Antivir Ther 2014; 19: 805-811.
33. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc B (Methodol) 1995; 57: 289-300.
34. Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, Giorgi JV. Elevated CD38 antigen expression on CD8R T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4R cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16: 83-92.
35. Duprez DA, Neuhaus J, Kuller LH, Tracy R, Belloso W, De Wit S, et al., INSIGHT SMART Study Group. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One 2012; 7: E44454.
36. Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr 2009; 51: 268-273.
37. Samson S, Mundkur L, Kakkar VV. Immune response to lipoproteins in atherosclerosis. Cholesterol 2012; 2012: 571846.
38. Sharma B. Oxidative stress in HIV patients receiving antiretroviral therapy. Curr HIV Res 2014; 12: 13-21.
39. Mandas A, Iorio EL, Congiu MG, Balestrieri C, Mereu A, Cau D, et al. Oxidative imbalance in HIV-1 infected patients treated with antiretroviral therapy. J Biomed Biotechnol 2009; 2009: 749575.
40. Skaggs BJ, Hahn BH, Sahakian L, Grossman J, McMahon M. Dysfunctional, pro-inflammatory HDL directly upregulates monocyte PDGFRbeta, chemotaxis and TNFalpha production. Clin Immunol 2010; 137: 147-156.
41. Cruz D, Watson AD, Miller CS, Montoya D, Ochoa MT, Sieling PA, et al. Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosy. J Clin Invest 2008; 118: 2917-2928.
42. Hossain E, Ota A, Karnan S, Takahashi M, Mannan SB, Konishi H, Hosokawa Y. Lipopolysaccharide augments the uptake of oxidized LDL by up-regulating lectin-like oxidized LDL receptor-1 in macrophages. Mol Cell Biochem 2015; 400: 29-40.
43. Hileman CO, Turner R, Funderburg NT, Semba RD, McComsey GA. Changes in oxidized lipids drive the improvement in monocyte activation and vascular disease after statin therapy in HIV. AIDS 2016; 30: 65-73.
44. Burdo TH, Lo J, Abbara S, Wei J, DeLelys ME, Preffer F, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis 2011; 204: 1227-1236.
45. Charles-Schoeman C, Watanabe J, Lee YY, Furst DE, Amjadi S, Elashoff D, et al. Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum 2009; 60: 2870-2879.
46. Samani NJ, Boultby R, Butler R, Thompson JR, Goodall AH. Telomere shortening in atherosclerosis. Lancet 2001; 358: 472-473.
47. Steinberg D,Witztum JL. Oxidized low-density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol 2010; 30: 2311-2316.
48. Park KH, Jang W, Kim KY, Kim JR, Cho KH. Fructated apolipoprotein A-I showed severe structural modification and loss of beneficial functions in lipid-free and lipid-bound state with acceleration of atherosclerosis and senescence. Biochem Biophys Res Commun 2010; 392: 295-300.
49. Bowry VW, Stanley KK, Stocker R. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci U S A 1992; 89: 10316-10320.
50. Chandra S, Mondal D, Agrawal KC. HIV-1 protease inhibitor induced oxidative stress suppresses glucose stimulated insulin release: Protection with thymoquinone. Exp Biol Med (Maywood) 2009; 234: 442-453.